| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. [PubChem] (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17023534 (en)
|
| http://linked.open...gy/drugbank/group
| - approved (en)
- illicit (en)
|
| http://linked.open...drugbank/halfLife
| |
| http://linked.open...ugbank/indication
| - In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal. (en)
|
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Fluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open.../drugbank/synonym
| - 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one (en)
- 17α-Methyl-9α-fluoro-11β-hydroxytesterone (en)
- 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone (en)
- Fluoximesterona (en)
- Fluoxymesteronum (en)
- Testosterone, 9-fluoro-11beta-hydroxy-17-methyl- (en)
- 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one (en)
- 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone (en)
|
| http://linked.open...drugbank/toxicity
| - Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia. (en)
|
| http://linked.open...k/foodInteraction
| |
| http://linked.open...nk/proteinBinding
| - Very high (99%) with 80% to sex hormone binding globulin, 19% to albumin. (en)
|
| http://linked.open...ynthesisReference
| - U.S. Patent 2,793,218 U.S. Patent 2,813,881 (en)
|
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...ogy/drugbank/logS
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...nd-Acceptor-Count
| |
| http://linked.open...-Bond-Donor-Count
| |
| http://linked.open...drugbank/InChIKey
| |
| http://linked.open...urface-Area--PSA-
| |
| http://linked.open...nk/Polarizability
| |
| http://linked.open...bank/Refractivity
| |
| http://linked.open...atable-Bond-Count
| |
| http://linked.open...ugbank/absorption
| - Oral absorption is less than 44%. (en)
|
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...gbank/containedIn
| |
| http://linked.open...k/Bioavailability
| |
| http://linked.open...bank/Ghose-Filter
| |
| http://linked.open...nk/MDDR-Like-Rule
| |
| http://linked.open...ank/Melting-Point
| |
| http://linked.open...k/Number-of-Rings
| |
| http://linked.open...siological-Charge
| |
| http://linked.open...bank/Rule-of-Five
| |
| http://linked.open...tional-IUPAC-Name
| |
| http://linked.open...strongest-acidic-
| |
| http://linked.open...-strongest-basic-
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)